EyeGate Pharmaceuticals
EyeGate Pharma | Advanced therapeutics and drug delivery mechanisms for ophthalmic care.
Launch date
Market cap
-
Enterprise valuation
€84—125k (Dealroom.co estimates Jan 2010.)
Share price
$37.08 EYEG
Waltham Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Series A | ||
$2.0m | Series B | ||
$15.0m | Series C | ||
N/A | $490k | Debt | |
$23.0k | Series D | ||
N/A | $5.9m | Series D | |
N/A | N/A | IPO | |
N/A | $3.8m | Post IPO Debt | |
N/A | $1.9m | Post IPO Equity | |
N/A | $8.0m | Post IPO Equity | |
N/A | $10.8m | Post IPO Equity | |
* | N/A | $6.0m | Post IPO Equity |
* | N/A | $3.1m | Post IPO Equity |
* | $45.0m | Post IPO Equity | |
Total Funding | €20.8m |
Recent News about EyeGate Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by EyeGate Pharmaceuticals
EditACQUISITION by EyeGate Pharmaceuticals Dec 2020
ACQUISITION by EyeGate Pharmaceuticals Mar 2016